<DOC>
	<DOCNO>NCT00896129</DOCNO>
	<brief_summary>Rationale : At present , virtually evidence exists regard mid long-term patient-reported health outcome ( e.g. , health related quality life-HRQOL ) CML patient treat Imatinib . Purpose : result research provide preliminary evidence-based data number issue patient ' perspective , include adherence therapy issue .</brief_summary>
	<brief_title>Mid-to Long-Term Outcomes Chronic Myeloid Leukemia ( CML ) Patients With Complete Cytogenetic Response After Imatinib First Line Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary : investigate number mid long-term HRQOL issue Chronic Myeloid Leukemia ( CML ) patient complete cytogenetic response treat Imatinib First Line Therapy . Secondary evaluation : - Psychological wellbeing . - Fatigue . - Adherence therapy issue . - Symptom burden . - Possible association social-demographic clinical variable patient report health outcome . OUTLINE : This multicenter study . SAMPLE SIZE : Sample size estimation perform consider nature study lack preliminary data hypothesize number possible eligible patient center . DURATION OF THE STUDY : The recruitment period estimate approximately 6 12 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Age 18 year . CML patient meet follow criterion : Started IM therapy early chronic phase ( ECP ) . Have undergoing treatment IM , first line therapy , least three year regardless current prescribe dose IM . In complete cytogenetic response ( CCgR ) clinical evidence disease progression accelerate phase ( AP ) blast crisis ( BC ) . Able read write Italian . Freedom psychiatric condition may confound HRQOL evaluation . Informed consent provide . CML patient initially diagnose AP BC start therapy IM late chronic phase ( LCP ) . Having receive kind treatment prior IM therapy ( except hydroxyurea and/or anagrelide ) . Patients new primary malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Health Outcomes Research</keyword>
	<keyword>CML</keyword>
</DOC>